How did we become the first Anti-viral mask

How did we become the first Anti-viral mask

A primary goal of our active protection technologies, including the antiviral face masks, is to use only extremely safe components to achieve unexpected or unexpectedly strong activities for protecting people against environmental hazards such as viruses, bacteria, air pollution or allergens.  We are committed to best-in-class protective products with absolutely no safety concerns.
Medical face masks are usually made from several layers of textiles laminated together.  The initial idea behind the active antiviral face mask was to treat a middle layer of a mask textile with a dye that we believed would actively bind airborne viruses such as influenza, trapping viruses in that layer and protecting the user.
A simple extension of the basic virus binding activity was to add something to that trapping layer that would actively destroy viruses that are trapped, to provide further protection.  We found that small amounts of copper and zinc, in amounts innocuous to people, could rapidly destroy viruses so that they could no longer infect human cells.  As a final boost, we devised a coating for the outer layer of the mask that would wick any infectious airborne droplets (from sneezes or coughs) that might contact the mask from the surface into the active antiviral layer below.
RK RespoKare Anti-Viral Mask function mechanics
 
In the United States, face masks intended to protect against the spread of infections must be submitted to the FDA for approval as medical devices.  The FDA has rigorous standards for validation of activity of antimicrobial or antiviral materials in medical devices.  They required that our mask must be able to rapidly destroy influenza viruses by a factor of more than 10,000 versus identical mask material not treated with the RespoKare antiviral agents.  In other words, if 1 million virus particles were applied to the mask material, and if untreated mask material trapped half of that number in the fine meshwork that makes up mask textiles, leaving 500,000 live virus particles, the RK RespoKare Anti-Viral mask material would have to destroy more than 99.99% of those infectious viruses, or only 50 virus particles, which is below number that can be detected, as there are too few to sustain an infection of human cells.   We were able to show that the RK RespoKare Anti-Viral mask could meet these standards after only 5 minutes of contact between flu virus and the mask.  We showed this with at least 18 different strains of flu virus, demonstrating that the activity of the mask was independent of the strain differences that otherwise determine whether a vaccine or antiviral drug could work against a specific strain.  All testing was performed by an accredited, independent testing laboratory.  We also showed that the antiviral face mask could inactivate a number of other airborne viruses and bacteria that cause infections in people.
In acknowledgment of this technical achievement, the FDA created a new category specifically for the Innonix antiviral mask, as the first, and still only, legally marketed “Surgical Mask with Antimicrobial Agent” in the US.
RK RespoKare Test Results in inactivating flu viruses

Subtype

Isolate

Results

INFLUENZA A

H1N1

Pandemic H1N1, A/California/04/2009

Human (H1N1), A/Brisbane/59/2007

Human (H1N1), A/Wisconsin/10/1998

Human (H1N1), A/NewJersey/8/1976

Swine (H1N1), A/Swine/1976/1931

Human (H1N1) A/PuertoRico/8/1934

≥99.99%  (≥4.02 ± 0.00)* @ 5 minutes

>99.99% (4.94 ± 0.00) @ 5 minutes

≥99.99% (≥4.16 ± 0.21)*@ 5 minutes

>99.99% (4.41 ± 0.28) @ 5 minutes

≥99.99% (≥4.16 ± 0.21)*@ 5 minutes

≥99.99% (≥ 4.49 ± 0.14)* @ 5 minutes

H2N2

Human (H2N2), A/2/Japan/305/1957

≥99.99% (≥4.63 ± 0.00)*@ 5 minutes

H3N2

 

Human (H3N2), A/Brisbane/10/2007

Human (H3N2), A/Wisconsin/67/2005

Human (H3N2), A/HongKong/8/1968

Human (H3N2), A/Victoria/3/1975

≥99.99% (≥4.34 ± 0.00)*@ 5 minutes

≥99.99% (≥4.13 ± 0.00)* @ 5 minutes

≥99.99% (≥4.06 ± 0.14)*@ 5 minutes

>99.99% (4.10 ± 0.16) @ 5 minutes

H3N8

Equine (H3N8), A/Equine/2/Miami/1963 

≥99.99% (≥4.53 ± 0.22)*@ 5 minutes

H5N1

Avian (H5N1), NIBRG-14

≥99.99% (≥4.55 ± 0.00)*@ 5 minutes

H5N2

Duck (H5N2), A/Duck/PA/10218/84

≥99.99% (5.02 ± 0.54)*@ 5 minutes

H9N2

Avian (H9N2), A/Turkey/Wisconsin/1966

≥99.99% (4.04 ± 0.08)*@ 5 minutes

INFLUENZA B

B

Human, B/Brisbane/60/2008 (Victoria Lineage)

Human, B/Florida/4/2006 (Yamagata Lineage)

Human, B/Lee/1940

≥99.99% (≥3.97 ± 0.00)*@ 5 minutes

≥99.99% (≥4.00 ± 0.00)*@ 5 minutes

≥99.99% (≥4.05 ± 0.00)* @ 5 minutes